Samsung Biologics has signed a contract worth 111.2 billion won ($77 million) with an undisclosed U.S. pharmaceutical firm to provide contract manufacturing organization (CMO) services.

The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few ...

Samsung Biologics, the country’s leading pharmaceutical contract manufacturing organization (CMO), announced Tuesday it has secured its largest-ever deal, valued at over 2 trillion won ($1.4 billion).

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...

Study Forecasts 7.0% CAGR, with the CDMO Market Expanding from $136.6 Billion in 2024 to $191.6 Billion by 2029, Fueled by Increased Demand for Outsourced Drug Development and Manufacturing.Boston, ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Marks a significant advancement in offering new treatment options for patients with rare diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and ...

Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...